Top Canadian CEOs will earn more by today than average working person does in 2017

Click to play video: 'Canadian CEO salaries soar to new heights'
Canadian CEO salaries soar to new heights
WATCH ABOVE: By lunchtime today the top CEO’s in Canada had already made more than the average Canadian does in a year. It highlights a growing gap between rich and poor but can anything be done? Mike Drolet reports – Jan 3, 2017

TORONTO – Before noon today, Canada’s highest-paid CEOs will earn more than the average working person’s income for all of 2017.

That’s the conclusion of the Canadian Centre for Policy Alternatives, an Ottawa-based think-tank that has tracked CEO compensation in this country for a decade.

It says this year’s elite group of chief executive officers will earn the average, full-time Canadian wage by 11:47 a.m. on Jan. 3 – the second working day of 2017.

Last year, it would have taken about half an hour longer – until 12:18 p.m. on the second working day of 2016.

Hugh Mackenzie, a Toronto-based independent economist who wrote the Policy Alternatives report, says the clock analogy is a powerful way to illustrate a widening gap between what top executives get paid and what average Canadian workers earn.

Story continues below advertisement

READ MORE: How justified are top Crown corporation CEO salaries in Saskatchewan?

“There’s clearly been an explosion in the compensation of senior executives in Canada and the United States. And that serves as a very potent symbol, I think, of the growth of income inequality,” Mackenzie said in an interview.

This year’s report, based on information released by Canadian publicly traded companies in 2016, estimates the average compensation of the Top 100 chief executives was $9.5 million in 2015 – 193 times the average annual industrial wage.

WATCH BELOW: Examining how justified top Crown CEO salaries in Saskatchewan

Click to play video: 'Examining how justified top Crown CEO salaries in Saskatchewan'
Examining how justified top Crown CEO salaries in Saskatchewan

That’s up from $8.96 million in 2014 – 184 times the average annual industrial wage that year.

Mackenzie says the problem lies with the way CEOs earn this money – often with stock grants and stock options that can lead executives to make decisions that reward them in the short term rather than the company or public at large.

Story continues below advertisement

He suggests Ottawa should level the playing field by ending a tax break for proceeds from stock options

“The proceeds of stock options in Canada are taxed at half the rate of ordinary income,” Mackenzie says.

READ MORE: TransLink back on the hunt for new CEO; offering new compensation package

“The (Trudeau) government actually promised to get rid of that but then backed down in the face of opposition from the business community.”

“One of the things that I’m going to be watching with some interest is what the government does in its next budget with respect to that campaign commitment.”

Mackenzie says the trend to higher CEO compensation has been pretty consistent over the years – regardless of the broader economic downturns or shareholder attempts to get more say on executive pay.

But he admits there always seems to be at least one or two individual CEOs each year who are far ahead of the others, possibly distorting the overall averages in the Top 100.

READ MORE: CEO says he will cut his pay to give every employee a minimum wage of $70,000

Most of the year-over-year increase in the Policy Options report was due to just one person – Michael Pearson, formerly CEO of Valeant Pharmaceuticals – who vaulted to No. 1 with $182.9 million of compensation in 2015 from No. 15 at just under $11.35 million in 2014.

Story continues below advertisement

Pearson’s rise was due mostly to $179.4 million of share compensation in 2015 – a year when Laval, Que.-based Valeant was at times Canada’s most valuable company with a stock above $300 per share for a two-month stretch in the summer.

Since then, Valeant has lost more than 90 per cent of its market value following a series of problems – including U.S. investigations into price hikes for some of its drugs – that emerged before Pearson departed in early 2016.

Sponsored content